This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
=== China === China's relationship with opioids, particularly opium, goes back centuries, with significant use for medicinal purposes by the 7th century and increased demand in the 17th century due to smoking practices from Southeast Asia. The Opium Wars in the 19th century exacerbated the problem, leading to social and health crises. After 1949, under the Communist regime, strict legislation and punishment significantly reduced opioid use, creating a drug-free atmosphere by the 1950s. But with the economic reforms and open-door policies of the 1980s, drug abuse, including opiate dependence, reemerged as a major public health issue. From 2000 to 2020, the prevalence of OUD in China showed significant trends, though exact figures are hard to obtain due to underreporting. In 2004, Tang et al. reported approximately 1.14 million registered drug addicts, with over 75% being heroin addicts, suggesting a substantial burden, though the actual number is likely higher due to the hidden nature of drug use. This figure aligns with the understanding that official statistics often undercount, as noted in later reports like a 2019 Associated Press article that discussed pain pill addiction and suggested undercounting problems. Opioid abuse has been linked to significant health implications, particularly the spread of HIV/AIDS. In 2004, intravenous drug use was the most prevalent route of HIV transmission, accounting for 51.2% of cases, underscoring the public health threat. This suggests OUD and associated infectious illness therapies are needed.
Gallium (68Ga) gozetotide or Gallium (68Ga) PSMA-11, is a radiopharmaceutical made of 68Ga conjugated to a inhibitor of the enzyme prostate-specific membrane antigen (PSMA) known as Glu-Urea-Lys(Ahx)-HBED-CC. It is used for imaging prostate cancer by positron emission tomography (PET). The PSMA inhibitor specifically directs the radiolabeled imaging agent towards the prostate cancerous lesions in men. The most common side effects with gallium (68Ga)-radiolabelled gozetotide are tiredness, nausea (feeling sick), constipation and vomiting. Gallium (68Ga) gozetotide was approved for medical use in the United States in December 2021, and in the European Union in December 2022. It is the first drug approved by the US Food and Drug Administration (FDA) as a PET imaging agent of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
CaMKII has multiple modes of activation to cause the incorporation of AMPA receptors into the perisynaptic membrane. CAMKII enzyme is eventually responsible for the development of the actin cytoskeleton of neuronal cells and, eventually, for the dendrite and axon development (synaptic plasticity). The first is direct phosphorylation of synaptic-associated protein 97 (SAP97), a scaffolding protein. First, SAP-97 and Myosin-VI, a motor protein, are bound as a complex to the C-terminus of AMPARs. Following phosphorylation by CaMKII, the complex moves into the perisynaptic membrane. The second mode of activation is through the MAPK pathway. CaMKII activates the Ras proteins, which go on to activate p42/44 MAPK, which drives AMPAR insertion directly into the perisynaptic membrane.
=== Key organisations === Key figures in the early phases of the Vaal uprising in the Vaal Triangle area were the Vaal Civic Association VCA and the Congress of South African Students (COSAS). Both were affiliates of the UDF, a nationwide popular front of civic organisations which had been launched in August 1983 and which subsequently had played a leading role in boycotts of the 1984 general election. Some of the UDF's affiliates in black townships, notably in Atteridgeville, Kagiso, and Soweto, had organised local campaigns against the Koornhof Bills, and in 1983 the front had boasted that its involvement had contributed to low election turnouts at that year's council elections – though, according to Jeremy Seekings, its involvement was neither intensive nor well-organised. Most of the organisations at the forefront of the uprising considered themselves to be affiliates of the UDF, whether formally or informally. These included local civic associations as well as some national structures, such as the Release Mandela Committee. However, branches of the Azanian People's Organisation (AZAPO) were also involved in parts of the Cape Province and Transvaal, as were various unaffiliated and relatively autonomous groups, particularly militant youth groups, many of which were formed during the course of the uprising.
=== Metatropic dysplasia === Metatropic means "changing form" and refers to this form of skeletal dysplasia as there is an abnormality in the growth plates. Skeletal changes continue over time and may need surgical intervention to help protect the lungs. Symptoms starting at birth may be mild or can be fatal. There are recognizable features in individuals with this genetic disorder. Some are short stature, narrow chest, "facial features such as a prominent forehead, underdevelopment of the upper jaw, cheekbones and eye sockets (midface hypoplasia), and a squared-off jaw." It is considered a more severe skeletal dysplasia, but is very rare, with the exact number of those affected unknown. Prognosis is largely on a case-by-case basis depending on the severity, and life expectancy may not be impacted unless there are respiratory complications.
Sources: en.wikipedia.org
and B is the magnitude of the field. This means that the spin magnetization, which is proportional to the sum of the spin vectors of nuclei in magnetically equivalent sites (the expectation value of the spin vector in quantum mechanics), moves on a cone around the B field. This is analogous to the precessional motion of the axis of a tilted spinning top around the gravitational field. In quantum mechanics,
The 1987 report of National Cholesterol Education Program, Adult Treatment Panels suggests the total blood cholesterol level should be: < 200 mg/dL normal blood cholesterol, 200–239 mg/dL borderline-high, > 240 mg/dL high cholesterol. The American Heart Association provides a similar set of guidelines for total (fasting) blood cholesterol levels and risk for heart disease: Statins are effective in lowering LDL cholesterol and widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease. The average global mean total cholesterol for humans has remained at about 4.6 mmol/L (178 mg/dL) for men and women, both crude and age standardized, for nearly 40 years from 1980 to 2018, with some regional variations and reduction of total cholesterol in Western nations. More current testing methods determine LDL ("bad") and HDL ("good") cholesterol separately, allowing cholesterol analysis to be more nuanced. The desirable LDL level is considered to be less than 100 mg/dL (2.6 mmol/L).
A common assertion in the US and the UK is that heavy consumption of turkey meat—as seen during Thanksgiving and Christmas—results in drowsiness, due to high levels of tryptophan contained in turkey. However, the amount of tryptophan in turkey is comparable with that of other meats. Drowsiness after eating may be caused by other foods eaten with the turkey, particularly carbohydrates. Ingestion of a meal rich in carbohydrates triggers the release of insulin. Insulin in turn stimulates the uptake of large neutral branched-chain amino acids (BCAA), but not tryptophan, into muscle, increasing the ratio of tryptophan to BCAA in the blood stream. The resulting increased tryptophan ratio reduces competition at the large neutral amino acid transporter (which transports both BCAA and aromatic amino acids), resulting in more uptake of tryptophan across the blood–brain barrier into the cerebrospinal fluid (CSF). Once in the CSF, tryptophan is converted into serotonin in the raphe nuclei by the normal enzymatic pathway. The resultant serotonin is further metabolised into the hormone melatonin—which is an important mediator of the circadian rhythm—by the pineal gland. Hence, these data suggest that "feast-induced drowsiness"—or postprandial somnolence—may be the result of a heavy meal rich in carbohydrates, which indirectly increases the production of melatonin in the brain, and thereby promotes sleep.
Psychedelic drug use can cause hallucinogen-induced psychotic disorder (HIPD). HIPD is a form of substance-induced psychosis. The symptoms of HIPD are psychosis with paranoia, delusions, hallucinations, disorganized thinking, disorganized behavior, or insomnia that continue after the effects of the drug. Individuals with a personal or family history of mental illness are at the highest risk for hallucinogen-induced psychotic disorder. HIPD due to psychedelics is most commonly associated with LSD, but can be caused by DMT, mescaline, and psilocybin as well. Hallucinogen-induced psychotic disorder is a medical emergency. Without treatment, the psychosis can persist for weeks or months. An atypical antipsychotic medication such as aripiprazole, quetiapine, olanzapine, or risperidone is used to treat HIPD. Psilocybin-induced states of mind share features with states experienced in psychosis and researchers have called for investigation of the relationship. Hallucinogen-induced psychotic disorder has been reported with psychedelics in small percentages of individuals, and the rates appear to be higher in people with schizophrenia. The rate of hallucinogen-induced psychotic disorder is 0.6% in randomized controlled trials that exclude individuals with bipolar disorder or schizophrenia. In studies that included individuals with schizophrenia, 3.8% developed hallucinogen-induced psychotic disorder.
=== Cell signalling === The typical mode of cell signalling in the endocrine system is endocrine signaling, that is, using the circulatory system to reach distant target organs. However, there are also other modes, i.e., paracrine, autocrine, and neuroendocrine signaling. Purely neurocrine signaling between neurons, on the other hand, belongs completely to the nervous system.
Sources: en.wikipedia.org
Several studies in the past have relied on the assumption that a drug's action would not be compromised when a subject and/or drug are placed in altered environments. However, the effect of outer space on the subject has been a recent concern on drug delivery and mechanism. There is a need to modify drug doses and release profiles to achieve maximum drug efficacy in outer space due to environmental implications on the human body. There are several conditions that NASA has identified that impact human physiology, affecting the pharmacological capabilities of drugs: Space Radiation, Isolation and Confinement, Distance from Earth, Gravity fields, and Hostile/Closed Environments (RIDGE), affecting drug absorption, distribution, metabolism, and excretion.
However, some methods of deuteration analysis for molecules such as proteins, are performed in aqueous solution, which means that exchange will continue at a slow rate even after the reaction is quenched. Undesired deuterium-hydrogen exchange is referred to as back-exchange and various methods have been devised to correct for this.
=== Cryogenic processing === The field of cryogenics advanced during World War II when scientists found that metals frozen to low temperatures showed more resistance to wear. Based on this theory of cryogenic hardening, the commercial cryogenic processing industry was founded in 1966 by Bill and Ed Busch. With a background in the heat treating industry, the Busch brothers founded a company in Detroit called CryoTech in 1966. Busch originally experimented with the possibility of increasing the life of metal tools to anywhere between 200% and 400% of the original life expectancy using cryogenic tempering instead of heat treating. This evolved in the late 1990s into the treatment of other parts. Cryogens, such as liquid nitrogen, are further used for specialty chilling and freezing applications. Some chemical reactions, like those used to produce the active ingredients for the popular statin drugs, must occur at low temperatures of approximately −100 °C (−148 °F). Special cryogenic chemical reactors are used to remove reaction heat and provide a low temperature environment. The freezing of foods and biotechnology products, like vaccines, requires nitrogen in blast freezing or immersion freezing systems. Certain soft or elastic materials become hard and brittle at very low temperatures, which makes cryogenic milling (cryomilling) an option for some materials that cannot easily be milled at higher temperatures. Cryogenic processing is not a substitute for heat treatment, but rather an extension of the heating–quenching–tempering cycle.
==== Buprenorphine ==== Buprenorphine is used similarly to methadone, with some doctors recommending it as the best solution for medication-assisted treatment to help people reduce or quit their use of heroin or other opiates. It is claimed to be safer and less regulated than methadone, with month-long prescriptions allowed. It is also said to eliminate opiate withdrawal symptoms and cravings in many patients without inducing euphoria. Probuphine is an implantable form of buprenorphine lasting six months. Rates of buprenorphine use increased between 2003 and 2011, with sales increasing, on average, by 40%. Unlike methadone treatment, which must be performed in a highly structured clinic, buprenorphine, according to SAMHSA, can be prescribed or dispensed in physician offices. Patients can thereby receive a full year of treatment for a fraction of the cost of detox programs. Buprenorphine/naloxone is a combination medication that has been approved by the FDA in 2002 for treatment of opioid dependence. It is a combination medication that contains two separate drugs: buprenorphine and naloxone. Buprenorphine works as a partial opioid agonist. It is given in combination with Naloxone because Naloxone works as an opioid antagonist, meaning it will block the effects of the opioid medication. This combination medication can reduce a person's opioid withdrawal symptoms while they are discontinuing opioids after a period of long-term use.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.